Hispolon

Hispolon

SCHEMBL30875919

CC(=O)/C=C(O)/C=C\c1ccc(O)c(O)c1

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IAPP P10997 4/20 0.74
PTGS1 P23219 1/20 0.74
TTR P02766 3/20 0.66
KDM4E B2RXH2 2/20 0.66
HSD17B10 Q99714 2/20 0.66
APP P05067 2/20 0.66
MAPT P10636 2/20 0.66
PTPN1 P18031 2/20 0.66
DPP4 P27487 2/20 0.66
MMP1 P03956 2/20 0.66
MMP2 P08253 2/20 0.66
MMP9 P14780 2/20 0.66
MEN1 O00255 1/20 0.66
HDAC3 O15379 1/20 0.66
CA12 O43570 1/20 0.66
AKR1B10 O60218 1/20 0.66
ALDH1A1 P00352 1/20 0.66
CA1 P00915 1/20 0.66
CA2 P00918 1/20 0.66
LMNA P02545 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hispolon SCHEMBL15917285 1.00 IAPP (0.74) IAPPPTGS1TTRKDM4EHSD17B10
Hispolon SCHEMBL17414113 1.00 IAPP (0.74) IAPPPTGS1TTRKDM4EHSD17B10
Hispolon SCHEMBL15917284 1.00 IAPP (0.74) IAPPPTGS1TTRKDM4EHSD17B10
SCHEMBL1881134 0.85 IAPP (1.00) IAPPPTGS1TTRKDM4EHSD17B10
SCHEMBL29364807 0.85 IAPP (1.00) IAPPPTGS1TTRKDM4EHSD17B10
SCHEMBL1881133 0.85 IAPP (1.00) IAPPPTGS1TTRKDM4EHSD17B10
SCHEMBL16093483 0.84 BACE1 (0.68) IAPPPTGS1TTRKDM4EHSD17B10
SCHEMBL9907025 0.83 APP (0.60) TTRKDM4EHSD17B10APPMAPT
SCHEMBL9907021 0.83 APP (0.78) PTGS1KDM4EHSD17B10APPMAPT
SCHEMBL26737769 0.83 IAPP (0.59) IAPPPTGS1TTRKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3368056-B1 COMPOSITIONS AND METHODS FOR SENSITIZING LOW RESPONSIVE TUMORS TO CANCER THERAPY PANDURANGI RAGHOOTTAMA (US) 2025-08-20 EP disclosed
US-11957732-B2 Compositions and methods for sensitizing low responsive tumors to cancer therapy PANDURANGI RAGHOOTTAMA (US) 2024-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11957732-B2 Compositions and methods for sensitizing low responsive tumors to cancer therapy CASP3, BAX, BID IAPP 561/4885PTGS1 1876/4885TTR 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.